Pharmacological Scenarios in Translational Research: A Current Multidisciplinary Overview and Possible Developments

Author(s): Andrea Tinelli.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 3 , 2020

Become EABM
Become Reviewer

[1]
Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy - will it really be a breakthrough? Curr Pharm Des 2020; 26(3): 300-9.
[2]
Tinelli A, Kosmas IP, Mynbaev OA, Malvasi A, Sparic R, Vergara D. The biological impact of ulipristal acetate on cellular networks regulating uterine leiomyoma growth. Curr Pharm Des 2020; 26(3): 310-7.
[3]
Mynbaev OA, Stark M, Malvasi A, et al. The medical device applied to uterine fibroids morcellation: analysis of critical biological issues and drawbacks from a medical-legal prospective. Curr Pharm Des 2020; 26(3): 318-25.
[4]
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
[5]
Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486-94.
[6]
Mirghani H, Sturgis EM, Aupérin A, Monsonego J, Blanchard P. Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: a systematic review. Oral Oncol 2017; 67: 138-45.
[7]
Wollenberg B. Cancer Immunology and HPV. Recent Results Cancer Res 2017; 206: 243-8.
[8]
Balmagambetova S, Tinelli A, Mynbaev OA, et al. Human papillomavirus selected properties and related cervical cancer prevention issues. Curr Pharm Des 2020. In Press.
[9]
Icardi G, Costantino C, Guido M, et al. Burden and prevention of HPV. knowledge, practices and attitude assessment among pre-adolescents and their parents in Italy. Curr Pharm Des 2020; 26(3): 326-42.
[10]
Guido M, Bruno A, Tagliaferro L, et al. The worldwide human papillomavirus vaccination and the impact in a southern Italian region. Curr Pharm Des 2020; 26(3): 343-57.
[11]
Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev 2016; 29(3): 449-86.
[12]
Nguyen VTN, Simon L. Pertussis: the whooping cough. Prim Care 2018; 45(3): 423-31.
[13]
Gkentzi D, Katsakiori P, Marangos M, et al. Maternal vaccination against pertussis: a systematic review of the recent literature. Arch Dis Child Fetal Neonatal Ed 2017; 102(5): F456-63.
[14]
Gabutti G, Baccello V, Sandri F, Stefanati A. Rational, safety and effectiveness of pertussis immunization in pregnancy. Curr Pharm Des 2020. In Press.
[15]
Di Tommaso S, Cavallotti C, Malvasi A, et al. A qualitative and quantitative study of the innervation of the human non pregnant uterus. Curr Protein Pept Sci 2017; 18(2): 140-8.
[16]
Aguilar HN, Mitchell S, Knoll AH, Yuan X. Physiological pathways and molecular mechanisms regulating uterine contractility. Hum Reprod Update 2010; 16(6): 725-44.
[17]
Kosmas IP, Malvasi A, Vergara D, Mynbaev OA, Sparic R, Tinelli A. Adrenergic and cholinergic uterine innervation and the impact on reproduction in aged women. Curr Pharm Des 2020; 26(3): 358-62.
[18]
Maclaran K, Panay N. Current concepts in premature ovarian insufficiency. Womens Health (Lond) 2015; 11(2): 169-82.
[19]
Pargianas M, Kosmas IP, Apostolopoulou K, et al. Georgiou I. Pathways involved in premature ovarian failure: a systematic review of experimental studies. Curr Pharm Des 2020. In Press
[20]
Vergara D, Simeone P, Franck J, et al. Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics. EuPA Open Proteom 2016; 10: 31-41.
[21]
Millithaler JF, Cataldo R, De Nunzio G, Alfinito E. Aptamers which target proteins: what proteotronics suggests to pharmaceutics. Curr Pharm Des 2020; 26(3): 363-71.
[22]
Rozenblum GT, Lopez VG, Vitullo AD, Radrizzani M. Aptamers: current challenges and future prospects. Expert Opin Drug Discov 2016; 11(2): 127-35.
[23]
Parashar A. Aptamers in Therapeutics. J Clin Diagn Res 2016; 10(6): BE01-6.
[24]
Vergara D, Verri T, Damato M, et al. A hidden human proteome signature characterizes the epithelial mesenchymal transition program. Curr Pharm Des 2020; 26(3): 372-5.
[25]
Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 2010; 3(3): 385-96.
[26]
Roach KM, Bradding P. Ca (2+) signalling in fibroblasts and the therapeutic potential of K(Ca) 3.1 channel blockers in fibrotic diseases. Br J Pharmacol 2019. [Epub ahead of print].
[http://dx.doi.org/10.1111/bph.14939]
[27]
Manfroni G, Ragonese F, Monarca L, et al. New insights on kca3.1 channel modulation. Curr Pharm Des 2020. In press
[28]
Amiri A, Tehran MM, Asemi Z, et al. Role of resveratrol in modulating microRNAs in human diseases: from cancer to inflammatory disorder. Curr Med Chem 2019. [Epub ahead of print].
[http://dx.doi.org/10.2174/0929867326666191212102407]
[29]
Elshaer M, Chen Y, Wang XJ, Tang X. Resveratrol: an overview of its anti-cancer mechanisms. Life Sci 2018; 207: 340-9.
[30]
Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 2018; 58(9): 1428-47.
[31]
Dionigi L, Ragonese F, Monarca L, et al. Focus on the use of resveratrol as adjuvant in glioblastoma therapy. Curr Pharm Des 2020. In Press
[32]
Schulman S. Bleeding complications and management on anticoagulant therapy. Semin Thromb Hemost 2017; 43(8): 886-92.
[33]
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128(2): 178-84.
[34]
Panteleev MA, Andreeva AA, Lobanov AI. Differential drug target selection in blood coagulation: what can we get from computational systems biology models? Curr Pharm Des 2020. In Press


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 3
Year: 2020
Page: [296 - 299]
Pages: 4
DOI: 10.2174/138161282603200306092551

Article Metrics

PDF: 18
HTML: 2
EPUB: 1
PRC: 1